PMID- 31876976
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210423
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 9
IP  - 4
DP  - 2020 Feb
TI  - Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous 
      non-small-cell lung cancer: A retrospective study.
PG  - 1365-1373
LID - 10.1002/cam4.2791 [doi]
AB  - PURPOSE: This study aimed to assess the effect of nanoparticle albumin-bound 
      paclitaxel (nab-PTX) chemotherapy regimens in elderly patients (>/=70 years old) 
      with advanced squamous non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: 
      The clinical records of elderly patients aged >/=70 years with advanced squamous 
      NSCLC were reviewed retrospectively. All of these patients received nab-PTX, with 
      or without combination of chemotherapy in Shandong Cancer Hospital and Institute 
      between 1 July 2012 and 30 June 2017. We analyzed the toxicity profiles, 
      progression-free survival (PFS), overall survival (OS), objective response rate 
      (ORR), and disease control rate (DCR). RESULTS: Totally, 52 elderly patients with 
      squamous NSCLC were included in the analysis. For all patients, the ORR was 
      34.6%, the DCR was 80.8%, median PFS was 5.9 months (95% confidence interval 
      [CI]: 4.0-7.8 months), and median OS was 14.3 months (95% CI: 11.0-17.8 months). 
      Combination with chemotherapy significantly prolonged OS (19.3 vs 11.2 months, 
      P = .016), despite a nonsignificant improvement in PFS (7.1 vs 4.2 months, 
      P = .060) vs monotherapy. For patients who received nab-PTX as first-line 
      treatment, the median PFS and OS were 6.7 months and 17.2 months, respectively, 
      and the median OS in combination therapy subgroup was significantly higher than 
      that in monotherapy group (20.3 vs 11.2 months, P = .013). Meanwhile, the median 
      PFS and OS of patients with nab-PTX as second- or later-line treatment were 
      4.4 months and 13.3 months, respectively, but no survival benefit was achieved by 
      the combination chemotherapy when compared with single-agent chemotherapy. 
      Hematologic toxicities were the most common adverse events (AEs), which include 
      grade 3 or 4 neutropenia (13.7%), thrombocytopenia (4.1%), and anemia (6.8%). The 
      main nonhematologic toxicities were peripheral sensory neuropathy (39.7%), 
      followed by anorexia and nausea/vomiting. CONCLUSION: In elderly advanced 
      squamous NSCLC patients, the treatment of nab-PTX was effective and well 
      tolerated.
CI  - (c) 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Liu, Yang
AU  - Liu Y
AD  - Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
AD  - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, China.
FAU - Dong, Yinping
AU  - Dong Y
AD  - Department of Gastric Cancer, Tianjin Medical University Cancer Institute & 
      Hospital, Tianjin, China.
FAU - Zhu, Hui
AU  - Zhu H
AUID- ORCID: 0000-0001-9422-3886
AD  - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, China.
FAU - Jing, Wang
AU  - Jing W
AD  - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, China.
FAU - Guo, Hongbo
AU  - Guo H
AD  - Department of Thoracic Surgery, Shandong Cancer Hospital and Institute, Shandong 
      First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
FAU - Yu, Jinming
AU  - Yu J
AUID- ORCID: 0000-0001-5933-9912
AD  - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191226
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (130-nm albumin-bound paclitaxel)
RN  - 0 (Albumins)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Albumins/*administration & dosage/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Carcinoma, Non-Small-Cell Lung/diagnosis/*drug therapy/mortality/pathology
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/diagnosis/*drug therapy/mortality/pathology
MH  - Male
MH  - Paclitaxel/*administration & dosage/adverse effects
MH  - Progression-Free Survival
MH  - Retrospective Studies
PMC - PMC7013054
OTO - NOTNLM
OT  - adverse events
OT  - elderly
OT  - nab-PTX
OT  - squamous NSCLC
OT  - survival
COIS- None declared.
EDAT- 2019/12/27 06:00
MHDA- 2021/04/24 06:00
PMCR- 2019/12/26
CRDT- 2019/12/27 06:00
PHST- 2019/10/18 00:00 [received]
PHST- 2019/11/30 00:00 [revised]
PHST- 2019/12/05 00:00 [accepted]
PHST- 2019/12/27 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
PHST- 2019/12/27 06:00 [entrez]
PHST- 2019/12/26 00:00 [pmc-release]
AID - CAM42791 [pii]
AID - 10.1002/cam4.2791 [doi]
PST - ppublish
SO  - Cancer Med. 2020 Feb;9(4):1365-1373. doi: 10.1002/cam4.2791. Epub 2019 Dec 26.